Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7524992 | 0.83 | MAPK1 (0.47) | ALDH1A1SMN1; SMN2GAAMAPTMAPK1 | |
| SCHEMBL28536439 | 0.79 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2GAAMAPTMAPK1 | |
| SCHEMBL18190822 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2GAAMAPTMAPK1 | |
| SCHEMBL27916053 | 0.78 | TSHR (0.62) | ALDH1A1SMN1; SMN2GAAMAPTMAPK1 | |
| SCHEMBL16397679 | 0.77 | TDP1 (0.47) | ALDH1A1SMN1; SMN2MAPTMAPK1L3MBTL1 | |
| SCHEMBL945131 | 0.76 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPTMAPK1L3MBTL1 | |
| SCHEMBL31150407 | 0.76 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GAAMAPTKDM4E | |
| SCHEMBL4748764 | 0.76 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GAAMAPTKDM4E | |
| SCHEMBL17144681 | 0.76 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAPTMAPK1L3MBTL1 | |
| SCHEMBL1185557 | 0.75 | GPR35 (0.53) | ALDH1A1MAPTL3MBTL1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392390-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3288946-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20180186797-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3288946-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176177-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392390-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | ALDH1A1 2185/4885SMN1; SMN2 440/4885GAA 760/4885 |
| US-20180186797-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | ALDH1A1 2185/4885SMN1; SMN2 440/4885GAA 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.